- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04523922
Oxytocin to Enhance Integrated Treatment for AUD and PTSD (COPE+OT)
Oxytocin to Enhance Integrated Exposure-Based Treatment of Co-occurring Alcohol Use Disorder and PTSD
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Stacey Sellers, MS
- Phone Number: 843-792-5807
- Email: sellersst@musc.edu
Study Contact Backup
- Name: Sudie Back, PhD
- Email: backs@musc.edu
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29401
- Recruiting
- Medical University of South Carolina
-
Contact:
- Stacey Sellers, MS
- Phone Number: 843-792-5807
- Email: sellersst@musc.edu
-
Principal Investigator:
- Sudie Back, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female; U.S. military Veteran, any race or ethnicity; aged 18-70 years.
- Able to provide written informed consent.
- Meet DSM-5 diagnostic criteria for current moderate to severe alcohol use disorder.
- Meet DSM-5 diagnostic criteria for current PTSD as assessed by the CAPS-5.
- Participants may also meet criteria for a mood disorder (except bipolar affective disorder, see Exclusion Criteria) or anxiety disorders. Concurrent substance use disorders (e.g., marijuana) are acceptable provided alcohol is the participant's primary substance of choice.
- Participants taking psychotropic medications will be required to be maintained on a stable dose for at least 4 weeks before study initiation.
Exclusion Criteria:
- Meeting DSM-5 criteria for a history of or current psychotic or bipolar affective disorders, or with current suicidal or homicidal ideation and intent. Those participants will be referred clinically for services.
- Participants on psychotropic medications which have been initiated during the past 4 weeks.
- Acute alcohol withdrawal as indicated by CIWA-Ar scores >8.
- Pregnancy or breastfeeding for women.
- For MRI scan component: history of seizures or severe head injury, implanted metal devices or other metal (e.g., shrapnel). These participants will be eligible to enroll in the clinical trial but will not be eligible to participate in the neuroimaging component of the study.
- Currently enrolled in behavioral treatment for AUD or PTSD.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oxytocin Treatment Group
Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus intranasal Oxytocin. 40-IU dose of Oxytocin self-administered 30 minutes prior to the start of each weekly COPE session. |
40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
Other Names:
12 weekly sessions of COPE therapy for PTSD and AUD.
Other Names:
|
Active Comparator: Placebo Group
Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus placebo (intranasal saline spray). Intranasal dose of saline spray self-administered 30 minutes prior to the start of each weekly COPE session. |
12 weekly sessions of COPE therapy for PTSD and AUD.
Other Names:
Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in alcohol use
Time Frame: From baseline to week 12 and 3 and 6 month follow ups
|
Change in percent days abstinent and heavy drinking days as measured by the TimeLine Follow-Back (TLFB).
|
From baseline to week 12 and 3 and 6 month follow ups
|
Change in PTSD symptom severity - clinician rated
Time Frame: From baseline to week 12 and 3 and 6 month follow ups
|
Change in clinician-rated PTSD symptom severity will be measured with the Clinician Administered PTSD Scale for DSM-5 (CAPS-5).
|
From baseline to week 12 and 3 and 6 month follow ups
|
Change in PTSD symptom severity - self report
Time Frame: From baseline to week 12 and 3 and 6 month follow ups
|
Change in self-reported PTSD symptom severity will be measured with the PTSD Checklist for DSM-5 (PCL-5).
|
From baseline to week 12 and 3 and 6 month follow ups
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sudie Back, PhD, Medical University of South Carolina
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00103198
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTSD
-
University of PittsburghCompletedPTSD | Non PTSDUnited States
-
Imperial College Healthcare NHS TrustImperial College LondonRecruiting
-
VA Office of Research and DevelopmentUniversity of California, San DiegoRecruiting
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Active, not recruiting
-
Oregon Health and Science UniversityEnrolling by invitation
-
VA Office of Research and DevelopmentCompleted
-
VA Office of Research and DevelopmentPortland VA Medical CenterActive, not recruiting
-
VA Office of Research and DevelopmentSan Diego Veterans Healthcare SystemCompleted
-
Creighton UniversityCompleted
-
VA Eastern KansasTerminated
Clinical Trials on 40 IU Intranasal Oxytocin
-
Icahn School of Medicine at Mount SinaiRecruitingBorderline Personality DisorderUnited States
-
Maria de las Mercedes Perez RodriguezJames J. Peters Veterans Affairs Medical Center; VISN 3 Mental Illness Research...TerminatedSchizophrenia | Schizoaffective Disorder | Bipolar Disorder | Autism Spectrum Disorder | Borderline Personality Disorder | Schizotypal Personality Disorder | SPD | BPDUnited States
-
OptiNose ASUniversity of OsloCompletedHealthy Male AdultsNorway
-
Brown UniversityCompleted
-
Emory UniversityNational Institute of Mental Health (NIMH); John Templeton FoundationCompleted
-
Michigan State UniversityCompletedExercise | InsulinUnited States
-
University Health Network, TorontoCompletedInsulin Resistance, DiabetesCanada
-
University of Electronic Science and Technology...Completed
-
University of NebraskaNational Institute of Mental Health (NIMH)Terminated
-
Massachusetts General HospitalUnited States Department of DefenseRecruitingAutism Spectrum Disorder | Bone HealthUnited States